As part of Lytix Biopharma's pipeline, the company is exploring novel second generation oncolytic molecules for treatment of deep seated tumors.

LTX-401 is a novel oncolytic β-amino acid derivative with potential immunogenic properties. Two papers have recently been published in high-quality peer-reviewed journals as products of a collaboration with University of Tromsø, Norway, and Institute Gustav Roussy, France.

The data presented in these two papers indicate that LTX-401 stimulates immunogenic cell death through several pathways upstream of mitochondrial membrane permeabilization, and has the ability to induce complete regression in solid tumors.  LTX-401 is currently tested in pre-clinical liver cancer models.

The first paper entitled: “The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma”  was published in PLOS ONE (Eike et al, PLOS ONE. 2016). The second paper entitled: “The oncolytic compound LTX-401 targets the Golgi Apparatus” was recently published in Cell Death and Differentiation (Zhou et al. Cell Death and Differentiation, 2016).